News & Filings

Toolkit

Subscribe
RSS Feeds
Contact IR
Presentations

Sub Nav News & Filings

Press Releases

SEC Filings

Annual Reports and AGM

Quarterly Results

News & Filings

Year

Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments

May 13, 2024

OXFORD, United Kingdom, May 13, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and

Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer

May 01, 2024

Dr. Hooftman brings more than 25 years’ experience in international drug development including immunology, autoimmunity, hematology, oncology, and infectious diseases OXFORD, United Kingdom, May 01, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc, a

Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections

Apr 18, 2024

Primary safety endpoint met; VTP-200 was generally well-tolerated, with no treatment-related grade 3 or higher adverse events (AEs) or serious AEs (SAEs). Positive trends in clearance rate for both high-risk (hr)HPV (60%, Group 2) and cervical lesions (67%,Groups 2 and 5), were observed in the

Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments

Mar 20, 2024

OXFORD, United Kingdom, March 20, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc, announced its financial results for the year ended December 31, 2023, and an overview of the Company’s progress. Barinthus Bio is a clinical-stage biopharmaceutical

Cancer Research UK and VOLT open squamous oesophageal cancer cohort in immunotherapeutic trial

Mar 11, 2024

OXFORD and LONDON, UK, 11 March 2024 – Cancer Research UK’s Centre for Drug Development and Vaccitech Oncology Limited (VOLT), a strategic collaboration between Barinthus Biotherapeutics Plc and the Ludwig Institute for Cancer Research, have opened a new cohort in the Phase 1/2a MAGE clinical trial

Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones

Jan 05, 2024

Cash runway anticipated to be extended from Q2 2025 to Q4 2025 Data from multiple Phase 1 and 2 clinical trials expected in 2024 OXFORD, United Kingdom, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc, today provided a preliminary financial

Pagination

First page
Previous page
Page 1
Current page 2

Displaying 11 - 16 of 16